Literature DB >> 18468856

A new 'mechanistic-practical" framework for designing and interpreting randomized trials.

Paul J Karanicolas1, Victor M Montori, P J Devereaux, Holger Schünemann, Gordon H Guyatt.   

Abstract

Methodologists have traditionally categorized randomized controlled trials (RCTs) as explanatory (representing the ideal setting) and pragmatic (representing the real-world setting). Although this framework has greatly advanced the design and interpretation of RCTs, current interpretations of the explanatory-pragmatic framework suffer from two major limitations. First, they confound purpose with structure. Second, they ignore the varying perspective of those using RCT results to make clinical and policy decisions in the real world. The purpose of a trial should determine researchers' choices regarding the trial's structure and the structure of a trial determines the extent to which a decision maker will find the results useful. In this article, we introduce two terms that refer explicitly to the purpose of a trial: A trial is mechanistic to the extent that it addresses a biological relationship. In contrast, a trial is practical to the extent that it provides comprehensive information that bears directly on specific health care decisions. This revised framework facilitates investigators' choice of optimal trial design, and clinicians' optimal interpretation of RCT results. If our goal is clinical trials most relevant to individual patient decision making, we will eschew the use of trials that enroll patients unlikely to benefit (e.g., those with uncertain diagnosis); those likely to be noncompliant; treated by practitioners whose differing expertise is likely to result in differing outcomes; and permitting cointerventions that are likely to influence treatment effectiveness-i.e., the conventional pragmatic trial. Instead we will design, implement, and apply the results of practical trials to our patients.

Entities:  

Mesh:

Year:  2008        PMID: 18468856     DOI: 10.1016/j.jclinepi.2008.02.009

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  26 in total

1.  Efficacy, effectiveness, and behavior change trials in exercise research.

Authors:  Kerry S Courneya
Journal:  Int J Behav Nutr Phys Act       Date:  2010-11-12       Impact factor: 6.457

2.  Explaining pragmatic trials to pragmatic policy-makers.

Authors:  Malcolm Maclure
Journal:  CMAJ       Date:  2009-04-16       Impact factor: 8.262

3.  What kind of randomized trials do we need?

Authors:  Merrick Zwarenstein; Shaun Treweek
Journal:  CMAJ       Date:  2009-04-16       Impact factor: 8.262

4.  Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects.

Authors:  Sherrie H Kaplan; John Billimek; Dara H Sorkin; Quyen Ngo-Metzger; Sheldon Greenfield
Journal:  Med Care       Date:  2010-06       Impact factor: 2.983

5.  The Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) instrument was useful for refining a randomized trial design: experiences from an investigative team.

Authors:  Daniel L Riddle; Robert E Johnson; Mark P Jensen; Francis J Keefe; Kurt Kroenke; Matthew J Bair; Dennis C Ang
Journal:  J Clin Epidemiol       Date:  2010-06-17       Impact factor: 6.437

6.  Current use and costs of electronic health records for clinical trial research: a descriptive study.

Authors:  Kimberly A Mc Cord; Hannah Ewald; Aviv Ladanie; Matthias Briel; Benjamin Speich; Heiner C Bucher; Lars G Hemkens
Journal:  CMAJ Open       Date:  2019-02-03

Review 7.  Building useful evidence: changing the clinical research paradigm to account for comparative effectiveness research.

Authors:  Sheldon Greenfield; Sherrie H Kaplan
Journal:  J Comp Eff Res       Date:  2012-05       Impact factor: 1.744

Review 8.  A review of pragmatic trials found a high degree of diversity in design and scope, deficiencies in reporting and trial registry data, and poor indexing.

Authors:  Stuart G Nicholls; Kelly Carroll; Spencer Phillips Hey; Merrick Zwarenstein; Jennifer Zhe Zhang; Hayden P Nix; Jamie C Brehaut; Joanne E McKenzie; Steve McDonald; Charles Weijer; Dean A Fergusson; Monica Taljaard
Journal:  J Clin Epidemiol       Date:  2021-03-28       Impact factor: 6.437

9.  Intervention description is not enough: evidence from an in-depth multiple case study on the untold role and impact of context in randomised controlled trials of seven complex interventions.

Authors:  Mary Wells; Brian Williams; Shaun Treweek; Joanne Coyle; Julie Taylor
Journal:  Trials       Date:  2012-06-28       Impact factor: 2.279

10.  Considering usual medical care in clinical trial design.

Authors:  Liza Dawson; Deborah A Zarin; Ezekiel J Emanuel; Lawrence M Friedman; Bimal Chaudhari; Steven N Goodman
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.